Keywords: serono/alkermes, progress, r-hfsh, switzerland-based, serono, firm, alkermes
Serono/Alkermes to progress r-hFSH
Article | 17 May 2001
Switzerland-based Serono and US firm Alkermes intend to proceed with theclinical development of a novel, long-acting formulation of the former's ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
